Key result
Perirenal adipose tissue inflammation and accumulation in metabolic disorders are linked to the development and progression of chronic kidney disease and cardiovascular diseases.
Why the study?
Perirenal adipose tissue influences renal function and metabolism, emerging as an independent risk factor for chronic kidney disease and cardiovascular disease, prompting a review of how its alterations impact renal and cardiovascular function.
Modulating perirenal adipose tissue immunometabolism may offer novel pharmacological perspectives for treating chronic kidney disease and cardiovascular disease.
Perirenal adipose tissue assessment may aid risk stratification in metabolic disorders; leaves open targeted interventions for CKD and CVD.
A healthy adipose tissue (AT) is indispensable to human wellbeing. Among other roles, it contributes to energy homeostasis and provides insulation for internal organs. Adipocytes were previously thought to be a passive store of excess calories, however this view evolved to include an endocrine role. Adipose tissue was shown to synthesize and secrete adipokines that are pertinent to glucose and lipid homeostasis, as well as inflammation. Importantly, the obesity-induced adipose tissue expansion stimulates a plethora of signals capable of triggering an inflammatory response. These inflammatory manifestations of obese AT have been linked to insulin resistance, metabolic syndrome, and type 2 diabetes, and proposed to evoke obesity-induced comorbidities including cardiovascular diseases (CVDs). A growing body of evidence suggests that metabolic disorders, characterized by AT inflammation and accumulation around organs may eventually induce organ dysfunction through a direct local mechanism. Interestingly, perirenal adipose tissue (PRAT), surrounding the kidney, influences renal function and metabolism. In this regard, PRAT emerged as an independent risk factor for chronic kidney disease (CKD) and is even correlated with CVD. Here, we review the available evidence on the impact of PRAT alteration in different metabolic states on the renal and cardiovascular function. We present a broad overview of novel insights linking cardiovascular derangements and CKD with a focus on metabolic disorders affecting PRAT. We also argue that the confluence among these pathways may open several perspectives for future pharmacological therapies against CKD and CVD possibly by modulating PRAT immunometabolism.
No takes yet. Share an insight, caveat, or question.
Hammoud et al. (2021) conducted a review in Metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Perirenal adipose tissue inflammation and accumulation was evaluated. Perirenal adipose tissue inflammation and accumulation in metabolic disorders are linked to the development and progression of chronic kidney disease and cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: